Comparative Epidemiology of Gliosarcoma and Glioblastoma and the Impact of Race on Overall Survival: A Systematic Literature Review

Al's Comment:

This is similiar to an article I posted a few weeks ago, both show that there is a large discrepancy in both clinical trial participation as well as overall survival by race.    This is not acceptable. We are working on leveling the playing field by collaborating with the Society of Neuro-oncology as well as a group of research and other organizations to remove barriers to participation in clinical trials. 

 

Our copayment assistance program was a major help in this regard - as a major part of the survival difference is inability to afford treatments - however we ran out of money and our program is closed to new patients. We get calls every day asking for help and right now there are no copay programs open to help people on Temodar.  Many patients are sadly going without it.

 

Comparative Epidemiology of Gliosarcoma and Glioblastoma and the Impact of Race on Overall Survival: A Systematic Literature Review